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OBJECTIVES This study was performed to identify a target population of claudicants for propionyl-L-
carnitine treatment.
BACKGROUND Previous studies suggest that the efficacy of propionyl-L-carnitine in intermittent claudication
is greater in patients with severe functional impairment than in those with mild walking
disability.
METHODS After run-in, 485 claudicant patients were randomized to placebo or propionyl-L-carnitine
(1 g bid, po) and then stratified on the basis of maximal walking distance (cutoff point 250 m)
and maximal walking distance variability (cutoff point 25%). Treatment lasted 12 months.
Walking capacity was assessed by treadmill and quality of life by a questionnaire exploring
various aspects of daily life.
RESULTS In the target population, that is, patients who at baseline walked #250 m and showed a
maximal walking distance variability #25%, per-protocol analysis showed that the effect of
propinyl-L-carnitine was significantly greater than that with placebo for both maximal
walking distance and initial claudication distance (ICD). In the intention-to-treat population,
maximal walking distance increased by 62 6 14% on propionyl-L-carnitine and by 46 6 9%
(p , 0.05) on placebo, while no difference between treatments was observed for ICD. The
beneficial effect of propionyl-L-carnitine was confirmed when data of the target population
were pooled with those of patients who at baseline walked #250 m and showed a .25%
maximal walking distance ,50% variability. Actually, maximal walking distance increased by
98 6 16% in the propionyl-L-carnitine group and by only 54 6 10% in the placebo group
(p , 0.01). The corresponding values for ICD were 99 6 21% and 51 6 8% (p , 0.05). For
patients with baseline maximal walking distance .250 m, no difference between treatments
was observed.
CONCLUSIONS Claudicants with maximal walking distance #250 m benefited from the use of propionyl-
L-carnitine, with improvement in walking distance and quality of life. However, patients with
mild functional impairment (i.e., walking distance .250 m) showed no response to
propionyl-L-carnitine. (J Am Coll Cardiol 1999;34:1618–24) © 1999 by the American
College of Cardiology
Patients with peripheral arterial disease have alterations in
carnitine metabolism that seem to be related to the severity
of circulatory insufficiency (1–4). In such patients, carnitine
supplementation restores a normal carnitine homeostasis,
improves the efficiency of oxidative phosphorylation and
lessens symptoms of claudication (4,5). Propionyl-L-
carnitine, one of the most potent analogues of carnitine (6),
exerts a greater effect on walking capacity than that with an
equimolar dose of carnitine (7). When given orally, it has
been reported to be a well-tolerated drug, effective in
improving walking capacity and quality of life in patients
with intermittent claudication (8,9).
Propionyl-L-carnitine efficacy seems to be greater in
patients with the lowest walking capacity than in those with
mild functional impairment (9). This observation, however,
is based on a post hoc analysis and, consequently, may be
affected by unequal distribution of the prognostic variable.
The present multicenter trial in Europe was undertaken to
prospectively investigate whether propionyl-L-carnitine
treatment outcome is more favorable in patients with severe
functional impairment than in those with less pronounced
walking disability.
METHODS
Patients. Patients affected by intermittent claudication for
at least one year were selected. The diagnosis was estab-
lished on the basis of history, Doppler examination and
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decrease in ankle-brachial pressure index (ABPI) after
exercise. Only patients with a resting ABPI ,0.80 that
decreased with exercise by at least 20% and a maximum
walking distance (MWD) between 50 and 400 m (as tested
by treadmill, speed 3 km/h, inclination 7%) were included in
the study. Three treadmill tests were conducted at three-
week intervals during the run-in period, and only patients in
whom the highest value of MWD during the three tests did
not exceed the lowest one by more than 50% were included.
The cardiovascular drugs allowed during the study were
diuretics, lipid-lowering agents, calcium antagonists, ACE
inhibitors, nitrates and aspirin. Major exclusion criteria were
reconstructive vascular surgery, angioplasty or sympathec-
tomy during the previous six months, peripheral neuropathy
and any other condition that limited exercise capacity.
Study design. A double-blind, placebo-controlled, parallel
design was adopted by 38 centers for the study. All patients
gave written informed consent before participation. Fur-
thermore, ethical approval for the study was obtained at all
participating centers. After the screening visit, all current
treatments for intermittent claudication were discontinued,
and patients entered a two-week phase during which they
were familiarized with the treadmill. A nine-week, single-
blind placebo, run-in period followed, during which stability
of the MWD was assessed. At the end of this period,
patients who met the inclusion criteria were randomly
allocated to placebo or propionyl-L-carnitine (1 g bid, po).
At randomization, patients were stratified on two variables:
MWD (cutoff point 250 m) and MWD variability (cutoff
point 25%). Thus, patients were divided into four strata
(Table 1). S1 population (i.e., patients who at baseline
walked #250 m and showed a MWD variability #25%)
was prospectively identified as the target population. The
double-blind medication lasted one year. Distance walked
before onset of claudication (initial claudication distance
[ICD]) and MWD measured by treadmill, as previously
described, were assessed monthly for the first two months
and then at two-month intervals. A quality-of-life question-
naire (Table 2) was completed by the patients at the end of
the run-in phase and three months apart, during the
treatment period, before the treadmill test. The items of the
questionnaire were rated by patients from 1 to 5 (1 5
extremely good function, 5 5 extremely poor function).
Thus, the higher the score, the worse the function. The
methodological approach to the construction of the ques-
tionnaire was that suggested by Jaeschke and Guyatt (10).
The questionnaire was translated into the languages of the
countries participating in the study and then retranslated
into Italian to confirm its accuracy.
Electrocardiographic and routine biochemical and hema-
tologic tests were performed at the end of the run-in period
and every two months during the double-blind phase. Drug
compliance was assessed by tablet count without the pa-
tient’s knowledge. Patients taking ,75% of the prescribed
dose were noncompliant and considered as dropouts. Al-
though all participants were advised of the beneficial effects
of a therapeutic walking program and nicotine abstinence,
no persistent effort was made to change their lifestyle.
Statistical analysis. Primary efficacy end point was the
change in MWD from baseline to the end of the treatment
period. The secondary end points were the change in ICD
and in quality-of-life questionnaire scores. For the compu-
tation of percent difference from baseline, we utilized the
following formula:
~month 12 value 2 baseline value 3 100!/baseline value
Abbreviations and Acronyms
ABPI 5 ankle-brachial pressure index
ICD 5 initial claudication distance
MWD 5 maximum walking distance
Table 1. Patients Stratification
Stratum
1 (S1)
Stratum
2 (S2)
Stratum
3 (S3)
Stratum
4 (S4)
MWD (m) # 250 # 250 . 250 . 250
MWD
variability
# 25% . 25 # 50% # 25% . 25 # 50%
MWD 5 maximum walking distance.
Table 2. Quality-of-Life Questionnaire
1. Walking/pain
a. Leg pain while walking
b. Going upstairs
c. Going downstairs
d. Walking speed
e. Recovery time after claudication pain
f. Leg pain at rest
2. Global physical function
a. Outdoor activies, e.g., shopping
b. Indoor activies, e.g., housework
c. Difficulty while standing
d. Tiredness
e. Feeling of physical limitation
3. Social function
a. Family
b. Friends
c. Leisure activities
d. Holiday
e. Work
f. Sexual life
4. Psychological attitudes
a. Sleep
b. Depression
c. Anxiety
d. Irritability
e. Feeling limitation
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Due to nonnormality of distributions and heterogeneity
of treatment variances, comparison of treatment effects was
made by a nonparametric procedure. We used the Gener-
alized Cochran-Mantel-Haenszel test stratified by center
according to randomization and conducted on within-
center standardized midranks of original changes from
baseline (11). Both per-protocol and intention-to-treat
population were analyzed.
Data are expressed as mean value 6 standard error.
Baseline values of ICD and MWD are the mean values of
the three measurements taken during the run-in phase.
RESULTS
Out of 1,773 patients screened, 501 patients were random-
ized. Among these, 16 (9 in the propionyl-L-carnitine
group, 7 in the placebo group) discontinued the study before
the first visit at month 1. The remaining 485 patients were
considered the intention-to-treat population (Table 3).
Only 328 patients completed the one-year protocol, 162 in
the propionyl-L-carnitine group and 166 in the placebo
group. Actually, 77 patients in the propionyl-L-carnitine
group and 80 in the placebo group dropped out of the study
for various reasons. In particular, five patients on propionyl-
L-carnitine and five on placebo died. Adverse events requir-
ing treatment discontinuation were 27 in the propionyl-L-
carnitine group and 30 in the placebo group. Protocol
violation was observed in 27 patients randomized to
propionyl-L-carnitine and 34 randomized to placebo. Fi-
nally, 18 patients on propionyl-L-carnitine and 11 on
placebo were lost to follow-up.
With the exception of walking performance, no difference
in clinical characteristics was observed between the four
subsets of patients obtained by stratification. No patients
stopped smoking during the study.
Effect on walking capacity. Results observed in S1 popu-
lation, that is, the target population, are shown in Table 4.
The per-protocol approach showed that, after 12 months of
treatment, the effect of propionyl-L-carnitine on both
MWD and ICD was significantly greater than that with
placebo. In the intention-to-treat population MWD in-
creased from 171 6 6 to 256 6 20 m in the placebo group
(n 5 83) and from 162 6 6 to 266 6 24 m in the
propionyl-L-carnitine group (n 5 80). Group differences
significantly favored propionyl-L-carnitine (p , 0.05).
Conversely, no difference between treatments was observed
for ICD.
In S2 population, after treatment, MWD increased from
169 6 9 to 283 6 41 m in the placebo group (n 5 26) and
from 184 6 8 to 411 6 58 m in the propionyl-L-carnitine
group (n 5 33). Although the superiority of propionyl-L-
carnitine versus placebo was markedly greater in this subset
of patients than in S1 population, difference between treat-
ments was not statistically significant. Similarly, no statis-
tical difference between treatments was observed for ICD,
which increased from 93 6 4 to 140 6 18 m in the placebo
group and from 107 6 5 to 185 6 31 m in the propionyl-
L-carnitine group. However, a significant improvement in
walking capacity with propionyl-L-carnitine was observed
when data of S1 and S2 population were pooled. Actually, in
S1 1 S2 population, per-protocol analysis showed that
MWD increased by 98 6 16% (from 169 6 5 to 342 6
30 m) in the propionyl-L-carnitine group (n 5 86) and only
by 54 6 10% (from 174 6 5 to 269 6 19 m) in the placebo
group (n 5 87). Difference between treatments was statis-
tically significant (p , 0.01). In the same patients, ICD
increased by 99 6 21% (from 104 6 4 to 193 617 m) on
propionyl-L-carnitine and by 51 6 8% (from 105 6 4 to
156 6 10 m) on placebo (p , 0.05). Figure 1 shows percent
changes in MWD and ICD observed throughout the study
in S1 and S1 1 S2 per-protocol population. By the
intention-to-treat approach, superiority of propionyl-L-
carnitine versus placebo did not reach statistical significance
in S1 1 S2 population, although in this subset of patients,
treatment differences at month 12 favored propionyl-L-
carnitine for MWD more so than in S1 population.
For patients with baseline MWD .250 m, no difference
Table 3. Characteristics of 485 Intention-to-Treat Patients
PLC Group
(n 5 239)
Placebo Group
(n 5 246)
Age (yr) 61.9 6 0.57 62.7 6 0.57
Male 204 (84) 195 (79)
Female 38 (16) 51 (21)
Smoker 208 (87) 209 (85)
Diabetic 12 (5) 12 (5)
Systolic blood pressure
(mm Hg)
143.7 6 1.08 144.2 6 1.05
Diastolic blood pressure
(mm Hg)
81.4 6 0.47 81.1 6 0.54
Ankle brachial index at rest 0.6 6 0.01 0.6 6 0.01
Initial claudication
distance (m)
141.5 6 4.59 143.0 6 4.32
Maximum walking
distance (m)
234.8 6 6.12 240.9 6 5.91
Data are presented as mean 6 SE or number (%) of patients.
PLC 5 propionyl-L-carnitine.
Table 4. Effect of Treatments on Walking Capacity in the Per-
Protocol Population Who at Baseline Showed MWD # 250 m
and MWD Variability # 25% (S1 Population)
Initial Claudication
Distance
Maximum Walking
Capacity
Placebo
(n 5 61)
PLC
(n 5 53)
Placebo
(n 5 61)
PLC
(n 5 53)
Baseline 110 6 5 102 6 6 176 6 7 159 6 7
Month 12 163 6 12 198 6 22 263 6 21 300 6 33
Percent change 48 6 9 109 6 31 46 6 9 87 6 20
p , 0.01 p , 0.01
PLC 5 propionyl-L-carnitine.
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between placebo and active treatment was observed either in
those with low (S3 population) and those with high (S4
population) MWD variability at baseline. Similarly, no
difference between treatments was observed in S3 1 S4
population. Per-protocol analysis showed that MWD in-
creased from 323 6 4 to 612 6 37 m in the placebo group
(n 5 79) and from 332 6 5 to 574 6 37 m in the
propionyl-L-carnitine (n 5 76). Initial claudication distance
changed from 196 6 7 to 381 6 33 m on placebo and from
202 6 8 to 367 6 31 m on propionyl-L-carnitine.
Effect on quality of life. In the per-protocol population,
the effect with propionyl-L-carnitine was found to be
greater than that with placebo for walking pain, global
physical activity and psychological attitudes, whereas social
function was not affected by active treatment (Table 5).
Similar results were observed with the intention-to-treat
approach. In S2 population, no difference between treat-
ments was observed. Conversely, in S1 1 S2 population,
per-protocol analysis showed that the effect of propionyl-
L-carnitine was significantly greater than that with placebo
for walking/pain (p , 0.05) and global physical activity
(p , 0.05). For patients who walked .250 m at baseline,
that is, S3 1 S4 population, no difference between treat-
ments was observed.
Adverse events and fate of the claudicant limb. In the
propionyl-L-carnitine group, 5 patients died during the
study (4 from cardiovascular causes), and 27 discontinued
the treatment because of the occurrence of serious adverse
events (cardiac 5 5, cerebral 5 3, peripheral 5 12, others 5
7). In the placebo group, deaths were 5 (4 from cardiovas-
cular causes), and the adverse events requiring drug discon-
tinuation were 30 (cardiac 5 5, cerebral 5 2, peripheral 5
13, others 5 10). Adverse events not requiring drug
Figure 1. Percent changes in ICD and MWD observed throughout the study in the S1 and S1 1 S2 per-protocol population. (Dotted
line) Changes in placebo group; (solid line) changes in propionyl-L-carnitine group.
Table 5. Quality-of-Life Questionnaire Scores: Changes from
Baseline to Month 12 in S1 Per-Protocol Population
PLC
(n 5 53)
Placebo
(n 5 61) p
Walking/pain 23.8 6 0.7 22.1 6 0.5 ,0.01
Global physical function 22.3 6 0.7 20.4 6 0.5 ,0.05
Social function 21.3 6 0.4 20.4 6 0.4 0.12
Psychological attitudes 22.1 6 0.6 20.3 6 0.4 ,0.01
PLC 5 propionyl-L-carnitine.
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discontinuation were 38 in the propionyl-L-carnitine group
and 98 in the placebo group; flu syndrome was the most
frequent effect.
With respect to the fate of the claudicant limb, during the
12 months of follow-up, none of the patients underwent
amputations, while two patients (0.8%) in the propionyl-L-
carnitine group required arterial reconstruction. There were
two thromboembolisms of the affected limb (0.8%) in the
propionyl-L-carnitine group and three (1.2%) in the pla-
cebo group. One patient in the propionyl-L-carnitine group
developed a venous ulcer in the nonaffected limb. Five
patients (2.1%) in the propionyl-L-carnitine group and 10
(4.1%) in the placebo group progressed to Fontaine’s stage
III (pain at rest), while progression to stage IV (trophic
lesions) was observed in two patients (0.8%) in the
propionyl-L-carnitine group and in none of the placebo
group. Given the spontaneous fluctuations in intermittent
claudication, only changes in MWD $50% from the study
entry to the final observation were assumed as clinically
significant. According to this criterion, in S1 1 S2 popula-
tion, walking capacity improved in 30 patients (34%) on
placebo and in 49 (57%) on propionyl-L-carnitine (p ,
0.01). Maximum walking distance deterioration $50% was
not observed in any patient of both groups. In S3 1 S4
population, MWD improved in 41 patients (54%) on
placebo and in 37 (48%) on propionyl-L-carnitine. Also in
this subpopulation, no patient experienced an MWD dete-
rioration $50%.
DISCUSSION
The present study was designed to verify the hypothesis that
propionyl-L-carnitine efficacy in intermittent claudication is
higher in patients with severe functional impairment than in
those with less pronounced walking disability.
Trial design and statistical analysis. The trial was de-
signed taking into account problems and inadequacies of
previous drug trials in intermittent claudication. Different
from previous studies not including patients with a walking
capacity variability .25% to 30%, the present trial also
included patients with a .25% MWD variability ,50%, to
increase the population representativeness. However, to
avoid a major imbalance between groups for a variable
related to outcome, patients were stratified on MWD
variability at baseline. Stratification on the maximum dis-
tance walked was necessary to balance the two treatment
groups respecting the number of patients with low and high
walking capacity in the groups. Treatment lasted 12
months, much more than the large majority of therapeutic
trials in intermittent claudication. This was done to be sure
that treatment tolerance to the active drug does not occur.
Maximum walking distance was chosen as primary efficacy
end point for two reasons. First, changes in carnitine
metabolism take place (12), and thus, carnitine supplemen-
tation needs (7), only when exercise is of sufficient intensity
to qualitatively alter muscle substrate metabolism. Further-
more, many patients with intermittent claudication are still
able to continue walking for a long distance after pain onset
in the affected leg and thus experience few limitations in
daily activities. Thus, MWD, which accurately reflects the
impairment experienced by such patients in daily life (13),
has greater clinical relevance than ICD.
The statistical analysis was performed both in the
intention-to-treat and per-protocol population. Intention-
to-treat is a rigorous analysis. In dropouts who provided at
least one postbaseline MWD value, the last valid observa-
tion was carried forward and used for the analyses at later,
missed visits. The disadvantage of the type of analysis,
however, is that it tends to mask treatment effects that
increase over time.
Walking capacity. This study indicates that claudicants
with baseline MWD #250 m, after 12 months of treatment
with propionyl-L-carnitine, walked a longer distance than
those who received placebo. This is a relevant result because
the overall clinical utility of pentoxifylline, the most widely
used drug for claudication, is limited by drug intolerance
and inconsistent clinical response (15–17). Two previous
studies reported that propionyl-L-carnitine improved
MWD versus placebo by 26% and 27%, respectively (8,14).
These improvements were observed in a general population
of claudicants and are lower than the 44% improvements
observed in our target population. In patients with baseline
MWD .250 m, no significant difference was found be-
tween treatments. Therefore, findings of the present study
are consistent with the previous observation that, in inter-
mittent claudication, only the most affected patients require
carnitine supplementation, because they, and not those with
mild functional impairment, have reduced availability of
endogenous carnitine to meet the increased metabolic de-
mand induced by walking (7).
Quality of life. Propionyl-L-carnitine-induced improve-
ment in walking capacity resulted in a real functional benefit
for claudicants. Actually, in S1 1 S2 population, a signifi-
cant improvement was observed for walking/pain, global
physical activity and psychological attitudes.
Concern is often expressed that quality of life methods
may not be equally valid for all countries. Westernized
countries, however, probably share a cultural uniformity of
life-style, values and health beliefs. Actually, quality of life
measures have been incorporated in several multinational
trials (18–20). Our questionnaire showed a high reliability,
as assessed by internal consistency and responses to retesting
(G. Brevetti, personal communication). Furthermore, it is
valid as evidenced by the finding that it discriminated
appropriately among patients with differing degrees of
functional impairment. Actually, baseline questionnaire
scores in S1 1 S2 population were higher than in S3 1 S4
population. Thus, it seems likely that the questionnaire
should have detected significant differences in quality of life
during treatment with propionyl-L-carnitine or placebo if
differences truly existed. Notable in this regard, is the fact
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that the results of the present study are consistent with those
of the Italian multicenter trials that evaluated the effect of
propionyl-L-carnitine on quality of life by the McMaster
Health Index Questionnaire (9).
Fate of claudicant limb. Previous observations indicate
that intermittent claudication has a benign course in terms
of local disease (21–23). In the present study, after one year
follow-up, no patient required amputation, and only 2 out
of 485 (0.49%) underwent surgical intervention for progres-
sion to incapacitating claudication. Critical limb ischemia
(pain at rest or trophic lesions in the affected limb) occurred
in 17 patients (3.5%). When considered separately, the two
treatment groups showed no difference in the number of
peripheral vascular events occurring during the study. Inter-
estingly, however, the number of patients who developed
pain at rest was smaller in the propionyl-L-carnitine group
than in the placebo group.
In S1 1 S2 population, the number of patients that at the
end of study experienced a MWD improvement $50% over
baseline was significantly higher in the propionyl-L-
carnitine group than in the placebo group. Conversely, no
difference between treatments was observed in S3 1 S4
population. In the overall placebo population, 71 out 166
patients who completed the study (42%) showed a MWD
improvement $50% after one year follow-up. This figure is
in keeping with earlier studies on the natural history of
intermittent claudication (24,25) but markedly higher than
that of recent studies reporting improvement in walking
capacity in 12% to 27% of the patients after a mean
follow-up of 2.5 years (21,23). In this regard, it is conceiv-
able that, in the setting of a formal therapeutic trial, the
magnitude of the placebo effect may reflect the patient’s
enhanced motivation in response to the intense surveillance.
This may account also for the fact that, in the present study,
no patient experienced a clinically significant deterioration
in walking capacity.
Laboratory findings. There were no clinically important
findings on repeat electrocardiogram, biochemical or hema-
tologic tests in either group. Furthermore, exercise-induced
changes in ABPI observed at baseline were not modified by
treatments.
Conclusion. For patients with mild functional impair-
ment, the treatment of choice should be the avoidance of
risk factors and the initiation of physical training. Con-
versely, for claudicant patients with MWD #250 m, the
use of propionyl-L-carnitine will lead to a high proba-
bility of a successful and clinically relevant treatment
outcome.
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APPENDIX
Study Organization Writing Committee: G. Brevetti
(Italy), C. Diehm (Germany), D. Lambert (UK)
Coordinating Committee: A. Amato (Roma), N. Ber-
gamini (Milano), A. Bettini (Roma), G. Brevetti
(Napoli), M. Corsi (Roma), C. Sabba` (Bari), C. Ulbricht
(Milano)
Scientific Committee: O. Albano (Bari), C. Diehm (Hei-
delberg), D. Lambert (Newcastle), J. Porter (Portland), J.
Rauwerda (Amsterdam)
Safety Committee: P. Bruzzi (Genova), G. Montanari
(Gubbio, PG), E.J. Saerens (Bruxelles)
Statistical Committee: A. Bacchieri (Roma), N. Bergamini
(Milano), P. Bruzzi (Genova), P. Pola (Roma)
Coordinating Centre: Department of Medicine, University
Federico II, Napoli, Italy
Study centers and principal investigators: Austria (24 pa-
tients): Karl Frazens University, Graz (E. Pilger, M. Lafer,
A. Doder); Landeskrankenhaus Salzburg, Salzburg (N.
Zinnagl, Drs. G. Oettl, K. Forstner)
Belgium (3 patients):St. Joseph Hospital Oostende, Oos-
tende (P. Depuydt)
Croatia (31 patients): Klinicka Bolnica “Merkur”, Zagreb
(D. Hlevnjak)
France (38 patients): C.H. Intercommunal St-Lambert,
Frejus (G. Adhoute, M. Bennani); Hospital Tenon, Paris
Cedex (M. Cloarec, P. Caillard, X. Mouren); Clinique du
Pont de Chaume, Montabaun (P. Dandine); Hospital
Cardiologique, Lille Cedex (G. Ducloux, P. De Groote, O.
Tison); Hospital Saint Michel, Vichy (M.C. Gagniere);
Centre Hospitalier, Albi (D. Galley, J. Scheffer); Clinique
de Re´education Cardio-Vasculaire, Saint-Orens de Gameville
(D. Garrigues); Hospital Pitie´-Salpe´tre´re, Paris, Cedex (P.
Godeau, O. Bletry); Hospital Saint Michel, Paris (P.
Lagneau, J. Launay); Hospital Saint-Louis, Paris (J. Rouffy,
P. Meiller)
Germany (140 patients): Gemeinschaftspraxis, Koln (B.
Bulling, M. Camci); Rehabilitationskrankenkhaus der Uni-
versitat, Karlsbad-Langenfeld (C. Diehm, T. Jansen); De-
partment for Vascular Surgery Kurhess, Kassel (J.D. Gruss);
Chirurgische Abteilung des Krankenhauses Proz, Koln (S.
Horsch); Medizinische Poliklinik Universitat Munchen,
Munchen (F. Spengel, E.M. Jung)
Holland (55 patients): St. Joseph Zickenhuis, DB Veld-
hoven (C.M.A. Bruyninckx); Slotervaartziekenhuis, EC
Amsterdam (J. Lawson, A.R.A. Dijkema); Saint Lucas
Ziekenhuis, CX Winshoten (R. Luyedijk); Academisch
Ziekenhuis der Vrije Universiteit, HV Amsterdam (A.A.J.
MacKaay); Rode Kruis Ziekenhuis, L.E. Beverwijk (W.E.
Tuinebreyer, H.J.D. Verdick); Streekziekenhuis Midden-
Twente Hengelo, D.L. Hengelo Ov (P. van der Sar);
Maasziekenhuis Boxmeer, HA Boxmeer (G.A.M. van
Gaal); Slingerland Ziekenhuis, B.L. Doetinchem (J.G.J.
van iersel, A.C. van Vliet)
Italy (55 patients): Universita` degli Studi di Napoli,
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Napoli (G. Brevetti, A.M. Di Donato); Policlinico di Bari,
Bari (O. Albano, C. Sabba`); Istituto Medicina Domani,
Genova (A. Di Somma, S. D’Agostino)
Russia (114 patients): Vascular Surgery Department,
Moscow (A.V. Chupin, S.A. Tsygelnikov); 2nd Moscow
Medical Institute, Moscow (V.M. Koshkin, N.A. Serge-
eva); Vascular Surgery Department, Moscow (G.S. Kro-
tovsky, T.F. Zabelskaya); Department of Vascular Disease,
St. Petersburg (Y.V. Lukjanov, G Sokerenko)
Slovenie (13 patients): Department of Surgery, Celje (A.
Vucaj, I. Zuran)
Switzerland (6 patients): Med Universitatsklinik Angi-
ologische Abteilung, Bern (F. Mahler, L. Krsmanovic)
United Kingdom (22 patients): Ronkswood Branch,
Worcester (R. Downing, E. Topham); Royal Victoria
Infirmary, Newcastle Upon Tyne (D. Lambert, N.F.W.
Redwood); Queens Medical Centre, Nottingham (G.S.
Makin, R. Lonsdale)
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